Mice immunized with both strategies were completely protected and elicited robust and durable humoral and cellular immune responses through 6 months, and these vaccines and strategies are suitable for reactive (emergency) and preventive (in endemic regions) use.
Abstract
Yersinia pestis is the etiological agent of pandemic-causing plague with no Food and Drug Administration (FDA)-approved vaccines. The natural emergence or intentional release of antimicrobial-resistant strains are alarming, necessitating development of new-generation vaccines and immunization strategies that produce rapid and durable immunity. Herein, we evaluated immediate (within 7 days) or long-term (6 months) protection and immune responses by combining patented live-attenuated vaccines (LAVs) with a trivalent adenovirus-type 5-based vaccine (Ad5-YFV) in C57BL/6 mice. Animals were immunized with either a two-dose prime-pull strategy (intramuscular [i.m.] injection of LAVs followed by intranasal [i.n.] instillation of Ad5-YFV, 21 days apart) or a 1-dose strategy by simultaneous administration of LAVs (i.m.) and Ad5-YFV (i.n.). Animals immunized with both strategies were either challenged after 6 months or, with the simultaneous strategy, 7 days post-vaccination in lethal pneumonic or bubonic Y. pestis CO92 infection models. Mice immunized with both strategies were completely protected and elicited robust and durable humoral and cellular immune responses through 6 months. Simultaneous vaccination also protected animals against bubonic (100%) and pneumonic (80%) challenges 7 days post-vaccination with rapid induction of immunoglobulin M (IgM), IgG3, and total IgG humoral responses. Thus, these vaccines and strategies are suitable for reactive (emergency) and preventive (in endemic regions) use.
Yersinia pestis
is a facultative intracellular bacterium that causes plague, which manifests in bubonic form and the more severe pneumonic and septicemic forms. There is no FDA-approved vaccine for plague, and those used in the past for human prophylaxis were suboptimal against aerosol infection or nonencapsulated s...
Michael L. Davies, Jennifer L. Dankmeyer, Nathaniel O. Rill et al.· Frontiers in Microbiology· 0 citations
Second-generation VXA-H5–02 is a promising vaccine candidate capable of inducing systemic and mucosal immunity, offering broad protection against HPAI, and significantly reduced illness, viral burden, and shedding.
Becca A. Flitter, Ka-Yan Tam, Laura J. Showalter et al.· Frontiers in Immunology· 0 citations
A two-dose vaccination regimen elicited high levels of antibodies and provided full protection against lethal challenge in A129 mice, preventing both death and joint swelling.
Jiang-Fan Li, Ting Fang, Li-Yuan Song et al.· Frontiers in Immunology· 0 citations
Dengue is one of the most rapidly spreading arboviral diseases worldwide, and the development of effective vaccines has long been constrained by antibody-dependent enhancement (ADE) and the difficulty of inducing protective immunity against multiple viral serotypes. Although several live-attenuated dengue vaccines have...
Background/Objectives: Brucellosis remains a widespread zoonosis, yet no licensed human vaccine exists and the live attenuated vaccines used in animals are unsuitable for people because of residual virulence and the risk of accidental infection. Recombinant platforms are attractive alternatives, but direct head-to-head...
B. Yespembetov, S. Alpysbayeva, M. Sarmykova et al.· Vaccines· 0 citations
Melioidosis, caused by
Burkholderia pseudomallei
, is a life‐threatening disease and a potential biological warfare agent. Currently, no licensed vaccine is available for prevention. To address this unmet need, we bioengineered an endotoxin‐free
Escherichia coli
strain to assemble biopolymer inclusions coated wit...
M. Kabir, Shu-Xiong Chen, Justine B. Bendo et al.· Advanced NanoBiomed Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.